Luc Teyton, professor in the Department of Immunology and Microbiology at Scripps Research, has received a five-year, $3.2 ...

HIGH POINT, N.C., Sept. 16, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it will deliver two oral presentations emphasizing the potential of TTP399 as an oral ...

Announcement of a podium presentation at a prestigious symposium, showcasing innovative research in cell therapy for type 1 diabetes. Presentation features promising clinical data on UP421, a novel ...

A multinational analysis and Swedish registry data show higher dementia mortality after age 80 and a twofold dementia risk in ...

“It’s well-established that people with type 1 diabetes (T1D) and chronic kidney disease (CKD) are at high risk of progression to kidney failure and cardiovascular events due to poor glycemic control, ...

Please provide your email address to receive an email when new articles are posted on . Semaglutide improved time in glycemic range in patients with type 1 diabetes and obesity using an automated ...

Patients with type 1 diabetes (T1D) who have risk factors such as obesity and hypertension can develop insulin resistance over time, a characteristic typically associated with type 2 diabetes (T2D).

Orforglipron (or-for-GLIP-ron) is an investigational, once-daily small molecule (non-peptide) oral glucagon-like peptide-1 (GLP-1) receptor agonist that can be taken any time of the day without ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. For the second time since 2019, the FDA in December ...

More than 588 million American adults are currently living with diabetes, the latest data shows — and between 90% and 95% of those cases are type 2 diabetes.Type 1 diabetes, although it only makes up ...